GENEVA & ARCHAMPS, France--(BUSINESS WIRE)--Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that data from single and multiple dose Phase I studies with the NOX 1 and 4 inhibitor, GKT137831, will be presented at Kidney Week 2012 (San Diego, October 30 – November 4).
